Business
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass., February 26, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates.
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/a587ba9946f654f63008739414f07640"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0qoB7eUPx4Z1MomgXvdnIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a587ba9946f654f63008739414f07640","width":480,"height":224}},"lazy":false},{"type":"text","content":"– Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025","length":135,"tagName":"p"},{"type":"text","content":"– Zocilurtatug pelitecan (zoci) on track to become Zai Lab’s first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026","length":200,"tagName":"p"},{"type":"text","content":"– Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE)","length":151,"tagName":"p"},{"type":"text","content":"– Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026","length":204,"tagName":"p"},{"type":"text","content":"Conference call and webcast today, February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT)","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., February 26, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates.","length":248,"tagName":"p"},{"type":"text","content":""2025 was a year of disciplined execution across both engines of our business with significant advancement across our global innovation pipeline and steady progress in our commercial business," said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. "We accelerated multiple global programs, including the rapid progression of zoci into pivotal development, enabled by our integrated U.S./China infrastructure which allows us to operate with speed and...